Gramatzki, M.

patient treatment myeloma study therapy cancer trial survival lenalidomide regimen melphalan blood cycle group novel agents erasmus mc prednisone thalidomide ef ficacy novel bortezomib department agent days 1-4 dexamethasone outcome comorbidity signi ն 75 years signi ficantly hematology combination university disease j clin oncol celgene effect phase disability response hospital maintenance vulnerability ficacy month condition palumbo janssen-cilag erasmu oncol result frailty high-dose 1-4 adult transplantation ficantly mortality improvement index randomized number 100 mg /d 6- wk cycles increase honoraria prognostic table grade incidence status 65-74 years 2012. meeting comorbid conditions toxicity health library high-dose dexamethasone 60 mg /m